Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Liquid breathing Stories

2010-01-13 12:23:00

DURHAM, N.C., Jan. 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) chairman and CEO Chris Stern outlined plans for the introduction of new products during a presentation today at the OneMedForum 2010 investor conference in San Francisco. During the brief presentation, limited by conference organizers to 10 minutes per company, Stern said Oxygen Biotherapeutics, Inc. plans to launch four products in its cosmetics line during 2010. They include an eye...

2009-12-04 10:08:00

DURHAM, N.C., Dec. 4 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company's Phase II-b, dose escalation, clinical trial in Switzerland for use of Oxycyte(TM) emulsion in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. "This trial is of invaluable importance in improving the outcome of patients with severe TBI. We hope to finally prove...

2009-10-20 07:30:00

DURHAM, N.C., Oct. 20 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced its expanded product development plan. The new clinical development pipeline now encompasses seven indications for the Oxycyte(TM) emulsion: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis. Oxycyte is the Company's perfluorocarbon (PFC)...

2009-09-24 07:30:00

DURHAM, N.C., Sept. 24 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. The invention provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or...

2009-09-23 07:30:00

DURHAM, N.C., Sept. 23 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier. "This approval from the Israeli Ministry of Health means that we can begin enrolling patients in a...

2009-09-10 00:16:00

DURHAM, N.C., Sept. 10 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) has posted a new Blog entry by company chairman and CEO, Chris Stern. In the blog, Stern discusses the company's proposed 1-for-15 reverse stock split. The Blog is available via a link on the home page of the company website at www.oxybiomed.com as well as via the Shareholder Forum link on the Investor Relations page of the website. About Oxygen Biotherapeutics, Inc. Oxygen...

2009-09-08 07:30:00

DURHAM, N.C., Sept. 8 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced that it has formally notified Vatea Fund of the company's achievement of a milestone under the Securities Purchase Agreement dated June 8, 2009, as amended September 1, 2009. The milestone is a Clinical Trial for Oxycyte in Traumatic Brain Injury Approved by Swissmedic. With the achievement of the milestone, the agreement calls for Vatea Fund to purchase 24 million shares of...

2009-05-13 16:04:00

COSTA MESA, Calif., May 13 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has signed a Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Federal laboratories of the United States Department of Defense. Under the agreement the company would provide information that would be used by NMRC and WRAIR for...

2009-05-07 07:30:00

COSTA MESA, Calif., May 7 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has filed an application with the U.S. Food and Drug Administration (FDA) to obtain orphan drug designation for Oxycyte(R) for the treatment of patients with severe, closed-head traumatic brain injury (TBI). Oxycyte is the company's perfluorocarbon (PFC) therapeutic oxygen carrier. If granted, orphan drug status would entitle Oxycyte to key regulatory...

2009-04-06 07:30:00

COSTA MESA, Calif., April 6 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) announced today that company Chairman and CEO, Chris Stern, has posted a new entry on his blog on the company website. The latest blog discusses the company's recent meetings in Zurich, Switzerland, further development plans for Oxycyte(R) in indications beyond traumatic brain injury, supply plans for clinical-grade Oxycyte, and plans for raising additional capital. The blog is...